# Beyond Hyperexcitability: A Review of Neural Mechanisms in Charles Bonnet Syndrome

**Authors:** Eric Altieri, Luca Battaglini

PMC · DOI: 10.3390/neurosci7020031 · 2026-03-03

## TL;DR

This review explores the complex brain mechanisms behind Charles Bonnet Syndrome, focusing on how visual hallucinations arise in people with vision loss.

## Contribution

The paper introduces an integrated model of CBS pathophysiology that goes beyond hyperexcitability, emphasizing desynchronization in visual processing pathways.

## Key findings

- CBS hallucinations may result from interactions between deafferentation-induced plasticity and neurotransmitter imbalances.
- Neuroimaging and modeling suggest desynchronization between bottom-up and top-down visual pathways is central to CBS.
- The findings challenge the traditional hyperexcitability model and propose a more nuanced neural mechanism.

## Abstract

Charles Bonnet syndrome (CBS) is characterized by complex visual hallucinations in visually impaired individuals who maintain intact cognitive function. Despite significant progress in understanding this condition, the precise neural mechanisms underlying CBS remain incompletely understood. This review synthesizes current evidence regarding the pathophysiology of CBS, with particular emphasis on emerging neurobiological models that extend beyond simple cortical hyperexcitability. Recent neuroimaging, neurophysiological, and computational modeling studies suggest that CBS hallucinations may arise from complex interactions among deafferentation-induced neural plasticity, neurotransmitter imbalances, and altered functional connectivity within visual processing hierarchies. The evidence increasingly points toward a model involving desynchronization between bottom-up and top-down visual processing pathways, rather than mere hyperexcitability of deafferented visual cortex. This integrated perspective has important implications for both the theoretical understanding of visual perception and the development of targeted therapeutic interventions.

## Linked entities

- **Diseases:** Charles Bonnet Syndrome (MONDO:0022140)

## Full-text entities

- **Genes:** CBS (cystathionine beta-synthase) [NCBI Gene 875] {aka HIP4}
- **Diseases:** mood symptoms (MESH:D019964), psychological (MESH:D000067073), fatigue (MESH:D005221), visual deterioration (MESH:C531604), mental illness (MESH:D001523), Deficit (MESH:D009461), psychosis (MESH:D011618), dementia with Lewy bodies (MESH:D020961), PAD (MESH:D001289), scotoma (MESH:D012607), neurocognitive disorders (MESH:D019965), perceptual deficits (MESH:D010468), anxiety (MESH:D001007), hyperactivity (MESH:D006948), Episodic hallucinations (MESH:D006212), injury to (MESH:D014947), dementia (MESH:D003704), AMD (MESH:D008268), schizophrenia (MESH:D012559), retinal damage (MESH:D012164), sensory deprivation (MESH:D012892), neural dysregulation (MESH:D021081), glaucoma (MESH:D005901), somnolence (MESH:D006970), vision loss (MESH:D014786), functional disorder (MESH:D003291), optic nerve pathology (MESH:D000080344), eye disease (MESH:D005128), falls (MESH:C537863), bipolar disorder (MESH:D001714), depression (MESH:D003866), Movement (MESH:D009069), cataract (MESH:D002386), confusion (MESH:D003221), CBS (MESH:D000075562), diabetic retinopathy (MESH:D003930), Hallucinatory (MESH:C000726587)
- **Chemicals:** quetiapine (MESH:D000069348), carbamazepine (MESH:D002220), valproate (MESH:D014635), olanzapine (MESH:D000077152), benzodiazepines (MESH:D001569), gabapentin (MESH:D000077206), SNRIs (-), GABA (MESH:D005680), donepezil (MESH:D000077265), serotonin (MESH:D012701), rivastigmine (MESH:D000068836), Acetylcholine (MESH:D000109), glutamine (MESH:D005973), glutamate (MESH:D018698)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13010627/full.md

---
Source: https://tomesphere.com/paper/PMC13010627